Pembrolizumab for Early Triple-Negative Breast Cancer
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Previous trials showed promising antitumor activity and an acceptable safety profile associated with pembrolizumab in patients with early triple-negative breast cancer. Whether the addition of pembrolizumab to neoadjuvant chemotherapy would significantly increase the percentage of patients with early triple-negative breast cancer who have a pathological complete response (defined as no invasive cancer in the breast and negative nodes) at definitive surgery is unclear. METHODS: In this phase 3 trial, we randomly assigned (in a 2:1 ratio) patients with previously untreated stage II or stage III triple-negative breast cancer to receive neoadjuvant therapy with four cycles of pembrolizumab (at a dose of 200 mg) every 3 weeks plus paclitaxel and carboplatin (784 patients; the pembrolizumab-chemotherapy group) or placebo every 3 weeks plus paclitaxel and carboplatin (390 patients; the placebo-chemotherapy group); the two groups then received an additional four cycles of pembrolizumab or placebo, and both groups received doxorubicin-cyclophosphamide or epirubicin-cyclophosphamide. After definitive surgery, the patients received adjuvant pembrolizumab or placebo every 3 weeks for up to nine cycles. The primary end points were a pathological complete response at the time of definitive surgery and event-free survival in the intention-to-treat population. RESULTS: At the first interim analysis, among the first 602 patients who underwent randomization, the percentage of patients with a pathological complete response was 64.8% (95% confidence interval [CI], 59.9 to 69.5) in the pembrolizumab-chemotherapy group and 51.2% (95% CI, 44.1 to 58.3) in the placebo-chemotherapy group (estimated treatment difference, 13.6 percentage points; 95% CI, 5.4 to 21.8; P<0.001). After a median follow-up of 15.5 months (range, 2.7 to 25.0), 58 of 784 patients (7.4%) in the pembrolizumab-chemotherapy group and 46 of 390 patients (11.8%) in the placebo-chemotherapy group had disease progression that precluded definitive surgery, had local or distant recurrence or a second primary tumor, or died from any cause (hazard ratio, 0.63; 95% CI, 0.43 to 0.93). Across all treatment phases, the incidence of treatment-related adverse events of grade 3 or higher was 78.0% in the pembrolizumab-chemotherapy group and 73.0% in the placebo-chemotherapy group, including death in 0.4% (3 patients) and 0.3% (1 patient), respectively. CONCLUSIONS: Among patients with early triple-negative breast cancer, the percentage with a pathological complete response was significantly higher among those who received pembrolizumab plus neoadjuvant chemotherapy than among those who received placebo plus neoadjuvant chemotherapy. (Funded by Merck Sharp & Dohme [a subsidiary of Merck]; KEYNOTE-522 ClinicalTrials.gov number, NCT03036488.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“improvement in overall survival has been reported in unresectable NSCLC patients and TNBC patients treated with anti PD-L1 antibody with chemotherapy”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Schmid et al., 2020
In the citing paper
“Immune checkpoint blockade (ICB) directed against programmed death-1 (PD-1) or programmed death-ligand 1 (PD-L1) has shown promising results in TNBC4–6, but the overall response rate of ICB is less than 20%7.”
Citations
Cites
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647
Edge, S. B., & Compton, C. C. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-010-0985-4 · Cited by 9,029
Cortazar, P., Zhang, L., Untch, M., Mehta, K., Costantino, J. P., Wolmark, N., Bonnefoi, H., Cameron, D., Gianni, L., Valagussa, P., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62422-8 · Cited by 4,742
Wolff, A. C., Hammond, M. E. H., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Cote, R. J., Dowsett, M., Fitzgibbons, P. L., Hanna, W. M., Langer, A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2775 · Cited by 4,434
Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer
Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Hegg, R., Im, S.-A., Shaw Wright, G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809615 · Cited by 4,350
Hammond, M. E. H., Hayes, D. F., Dowsett, M., Allred, D. C., Hagerty, K. L., Badve, S., Fitzgibbons, P. L., Francis, G., Goldstein, N. S., Hayes, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.6529 · Cited by 4,213
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Aebi, S., Davidson, T., Gruber, G., & Castiglione, M. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq159 · Cited by 2,842
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Cardoso, F., Kyriakides, S., Ohno, S., Penault-Llorca, F., Poortmans, P., Rubio, I. T., Zackrisson, S., & Senkus, E. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz173 · Cited by 2,214
Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy
Masuda, N., Lee, S.-J., Ohtani, S., Im, Y.-H., Lee, E.-S., Yokota, I., Kuroi, K., Im, S.-A., Park, B.-W., Kim, S.-B., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612645 · Cited by 1,888
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
Nanda, R., Chow, L. Q. M., Dees, E. C., Berger, R., Gupta, S., Geva, R., Pusztai, L., Pathiraja, K., Aktan, G., Cheng, J. D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.8931 · Cited by 1,477
Self-citation
Research works printed but not linked: 1
- Qi C Huang M Haiderali A et al. Association between pathological complete responses and long-term survival outcomes among triple-negative breast cancer patients receiving neoadjuvant chemotherapy. Presented at the NCCN Annual Conference Orlando March 21–23 2019.
Cited by
Items 901–1,000 of 1,004
Tumour-infiltrating lymphocytes in non-invasive breast cancer: A systematic review and meta-analysis
Caparica, R., Bruzzone, M., Agostinetto, E., Franzoi, M. A., Ceppi, M., Radosevic‐Robin, N., Penault-Llorca, F. M., Willard-Gallo, K. E., Loi, S., Salgado, R., et al. (2021) · The Breast · doi:10.1016/j.breast.2021.07.007 · Cited by 17
Wang, J., Zhang, Q., Li, Q., Mu, Y., Jing, J., Li, W., Li, W., Wang, J., Yu, G., Wang, X., et al. (2021) · Targeted Oncology · doi:10.1007/s11523-021-00823-4 · Cited by 18
Choudhary, P., Gogia, A., Deo, S. S., Sharma, D., Mathur, S. R., Batra, A., & Sagiraju, H. K. R. (2021) · Cancer Research Statistics and Treatment · doi:10.4103/crst.crst_197_21 · Cited by 17
Fujiwara, Y., Horita, N., Harrington, M. D., Namkoong, H., Miyashita, H., & Galsky, M. D. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03203-7 · Cited by 15
Clonal evolution in primary breast cancers under sequential epirubicin and docetaxel monotherapy
Venizelos, A., Engebrethsen, C., Deng, W., Geisler, J., Geisler, S., Iversen, G., Aas, T., Aase, H., Seyedzadeh, M., Steinskog, E. S., et al. (2022) · Genome Medicine · doi:10.1186/s13073-022-01090-2 · Cited by 16
“Of notice, PD-L1 expression was not predictive of response to immune checkpoint inhibitors on top of standard NAC regimens [54, 55], whereas the predictive value of homologous recombination deficiency (HRD) for PARP inhibitor efficacy still needs further validation in primary TNBC [56].”
BackgroundCancer therapy–related salivary dysfunction
Paz, C., Glassey, A., Frick, A., Sattar, S., Zaorsky, N. G., Blitzer, G. C., & Kimple, R. J. (2024) · Journal of Clinical Investigation · doi:10.1172/jci182661 · Cited by 26
Pauken, K. E., Alhalabi, O., Goswami, S., & Sharma, P. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.03.005 · Cited by 22
Li, Z., Chen, H., Wang, C., Deng, T., Huang, J., Ye, H., Chen, J., Huang, C. X., & Chen, Z. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114075 · Cited by 16
Moghaddam, A. S., Lu, K. Y., Nasrollahi, E., Oji, L., Homeniuk, A., Amosu, O., Chelysheva, D., & Brufsky, A. (2025) · npj Breast Cancer · doi:10.1038/s41523-025-00873-1 · Cited by 21
“Amongbreastcancerpatients, triple-negativebreastcancer(TNBC)bene fi ts the most from immune checkpointinhibitors(ICIs),especiallyinprogrammeddeath-ligand1(PD-L1) positive population 1,2 .”
Hunter, N. B., Parsons, H. A., Cope, L., Canzoniero, J. V., Navarro, F. C. P., El-Refai, S. M., Anampa, J. D. S., Sparano, J. A., Rimawi, M. F., Storniolo, A. M., et al. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-25-02934 · Cited by 16
Cost per Event Averted in Cancer Trials in the Adjuvant Setting From 2018 to 2022
Mousavi, I., Olivier, T., & Prasad, V. K. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.16058 · Cited by 16
Tang, A., Hoefer, R. A., Guye, M. L., & Bear, H. D. (2022) · Cancer Drug Resistance · doi:10.20517/cdr.2022.31 · Cited by 22
Yan, W., Wu, X., Wang, S., He, C., Zhong, L., Tang, P., Ren, L., Zhang, T., Qi, X., & Zhang, Y. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221107111 · Cited by 17
Howard, F. M., He, G., Peterson, J. R., Pfeiffer, J. R., Earnest, T. M., Pearson, A. T., Abé, H., Cole, J. A., & Nanda, R. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-022-06722-0 · Cited by 16
“Sensitivity and specificity were preserved across receptor subtypes, with the lowest sensitivity of 80.0% (95% CI 28.4 – 99.5) seen in the HR + /HER2-patients, and the lowest specificity of 86.5% (95% CI 71.2 – 95.5) seen in patients with TNBC.”
InfluentialJiang, S., Feng, R., Tian, Z., Zhou, J., & Zhang, W. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216076 · Cited by 17
Mabrouk, N., Racoeur, C., Shan, J., Massot, A., Ghione, S., Privat, M., Dondaine, L., Ballot, E., Truntzer, C., Boidot, R., et al. (2023) · Cancers · doi:10.3390/cancers15123129 · Cited by 19
“Several randomized trials combining chemotherapy with immune checkpoint inhibitors (ICI) have been subsequently initiated in TNBC, particularly in early TNBC [32,33].”
BackgroundWang, F., Lu, Q., Yu, H., & Zhang, X. (2023) · Cancer Management and Research · doi:10.2147/cmar.s411901 · Cited by 16
Manni, A., Sun, Y., Schell, T. D., Lutsiv, T., Thompson, H. J., Chen, K.-M., Aliaga, C. A., Zhu, J., & El‐Bayoumy, K. (2023) · Pharmaceuticals · doi:10.3390/ph16101422 · Cited by 19
“…we report here that dietary the administration of quercetin, a phytochemical with pleiotropic antitumor properties [29], enhances the antitumor action of Cyclophosphamide, a cytotoxic drug with significant immunogenic effects [4,5], which is part of the combination therapy used in TNBC [19].”
BackgroundInfluentialWescott, E. C., Sun, X., Ericsson, P. I. G., Hanna, A., Taylor, B. C., Sanchez, V. M., Bronzini, J., Opalenik, S. R., Sanders, M. E., Wulfkuhle, J. D., et al. (2024) · Cancer Research Communications · doi:10.1158/2767-9764.crc-23-0468 · Cited by 21
Kuryk, Ł., Mathlouthi, S., Wieczorek, M., Gad, B., Rinner, B., Malfanti, A., Mastrotto, F., Salmaso, S., Caliceti, P., & Garofalo, M. (2024) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2024.114300 · Cited by 18
Kumar, P., Singh, R., Sharma, D. K., Hassan, Q. P., Gopu, B., & Anãl, J. M. H. (2024) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2024.129795 · Cited by 16
Wang, C., Yuan, L., Wu, X., Wang, Y., Tian, H., Zhang, G., Wan, A., Xiong, S., Wang, C., Zhou, Y., et al. (2024) · BMC Medicine · doi:10.1186/s12916-024-03474-0 · Cited by 17
He, M., Hao, S., Ma, L., Xiu, B., Yang, B., Wang, Z., Xue, J., Chi, Y., Xiong, M., Chen, J., et al. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102700 · Cited by 23
Window of opportunity trials with immune checkpoint inhibitors in triple-negative breast cancer
Quintana, Á., Saini, K. S., Vidal, L., Peg, V., Slebe, F., Loibl, S., Curigliano, G., Schmid, P., & Cortés, J. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.103713 · Cited by 18
“More-over, since pembro has been approved in the early setting regardless of PD-L1 or nodal status, 14 there is a need to fi nd biomarkers that could help identify patients who may bene fi t from this combination or could potentially need only immunotherapy, a combination of immunotherapy with other…”
BackgroundIbrahim, M., Fathalla, Z. M. A., Fatease, A. M. A., Alamri, A. H., & Abdelkader, H. (2024) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2024.2412823 · Cited by 21
Egeland, E. V., Seip, K., Skourti, E., Øy, G. F., Pettersen, S., Pandya, A. D., Dahle, M. A., Haugen, M. H., Kristian, A., Nakken, S., et al. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02875-5 · Cited by 18
Naji, O., Ghouzlani, A., Rafii, S., Sadiqi, R. U., Kone, A.-S., Harmak, Z., Choukri, K., Kandoussi, S., Karkouri, M., & Badou, A. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1399754 · Cited by 23
“This suggests a possible feedback mechanism in which IL-10 production by Bregs promotes the generation of innate immune cells that enhance the persistence or quantity of Tregs in the TME (128).”
BackgroundResultRaghavendra, A. S., Zakon, D. B., Jin, Q., Strahan, A., Grimm, M., Hughes, M. E., Cherian, M. A., Vincuilla, J., Parker, T., Tarantino, P., et al. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.103973 · Cited by 17
“38,39 We conducted this study before the addition of pembrolizumab to NAT 38 became a standard treatment regimen for patients diagnosed with stage II-III eTNBC.”
Clinical Implications of Breast Cancer Intrinsic Subtypes
Ríos-Hoyo, A., Shan, N. L., Karn, P. L., & Pusztai, L. (2025) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-70875-6_21 · Cited by 23
Current and emerging biologic therapies for triple negative breast cancer
Shaikh, S. S., & Emens, L. A. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1801627 · Cited by 20
Tian, Y., Gao, A., Wen, Q., Wang, S., Zhang, S., Yang, X., Su, G., & Sun, Y. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.595655 · Cited by 18
Fattori, S., Gorvel, L., Granjeaud, S., Rochigneux, P., Rouviére, M.-S., Amara, A. B., Boucherit, N., Paul, M., Dauplat, M. M., Piana, J. T., et al. (2021) · Cancers · doi:10.3390/cancers13030441 · Cited by 18
Effect of concomitant use of antihypertensives and immune check point inhibitors on cancer outcomes
Kichenadasse, G., Miners, J. O., Mangoni, A. A., Rowland, A., Sorich, M. J., & Hopkins, A. M. (2021) · Journal of Hypertension · doi:10.1097/hjh.0000000000002799 · Cited by 19
Moving Towards Targeted Therapies for Triple-Negative Breast Cancer
Kagihara, J. A., Shagisultanova, E. I., Afghahi, A., & Diamond, J. R. (2021) · Current Breast Cancer Reports · doi:10.1007/s12609-021-00416-0 · Cited by 16
Combined endocrine and targeted therapy in luminal breast cancer
Cesca, M. G., Pandolfi, N. C., Maciel, D., Lima, J., Sanches, S. M., & Ponde, N. F. (2021) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1960160 · Cited by 19
Tarantino, P., Antonarelli, G., Ascione, L., & Curigliano, G. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1972968 · Cited by 14
Biomarkers of immunotherapy response in breast cancer beyond PD-L1
Chic, N., Brasó‐Maristany, F., & Prat, A. (2021) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06421-2 · Cited by 18
Ledys, F., Kalfeist, L., Galland, L., Limagne, E., & Ladoire, S. (2021) · Cancers · doi:10.3390/cancers13235999 · Cited by 21
Junjun, S., Jing, Z., Jie, P., Jian, C., Pan, Y., & Han, S. (2022) · Breast Cancer · doi:10.1007/s12282-022-01344-2 · Cited by 17
Qi, Y., Zhang, W., Jiang, R., Xu, O., Kong, X., Zhang, L., Fang, Y., Wang, J., & Wang, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.960323 · Cited by 16
“chemotherapy in this meta-analysis (Loibl et al., 2019; Cortes et al., 2020; Mittendorf et al., 2020; Schmid et al., 2020; Emens et al., 2021; Miles et al., 2021) (Table 1).”
Neoadjuvant chemotherapy modulates exhaustion of T cells in breast cancer patients
Rodríguez, I. J., Bernal-Estévez, D. A., Llano-León, M., Bonilla, C., & Parra-López, C. (2023) · PLoS ONE · doi:10.1371/journal.pone.0280851 · Cited by 16
Combinatorial Epigenetic and Immunotherapy in Breast Cancer Management: A Literature Review
Lee, Y.-T., Chuang, Y., & Chan, M. W. Y. (2020) · Epigenomes · doi:10.3390/epigenomes4040027 · Cited by 18
What are the advantages of neoadjuvant immunotherapy over adjuvant immunotherapy?
Bilušić, M. (2022) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2022.2069097 · Cited by 16
“0003 suggesting that the combination of immunotherapy and chemotherapy is effective preoperatively [12].”
BackgroundAraghi, M., Gharebakhshi, F., Faramarzi, F., Mafi, A., Mousavi, T., Alimohammadi, M., & Soleimantabar, H. (2024) · Current Gene Therapy · doi:10.2174/0115665232283880240301035621 · Cited by 23
Liu, Y., Zhang, G., Li, Q., Chen, J., Luo, W., Li, X., Suo, X., Su, L., Xu, Y., Liu, T., et al. (2024) · Chemical Engineering Journal · doi:10.1016/j.cej.2024.151437 · Cited by 15
Ademuyiwa, F. O., Ma, C. X., Weilbaecher, K. N., Suresh, R., Peterson, L. L., Bose, R., Bagegni, N. A., Rigden, C. E., Frith, A. E., Clifton, K., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-3145 · Cited by 24
Conte, P., Dieci, M. V., Bisagni, G., Schmid, P., Zambelli, A., Piacentini, F., Laurentiis, M. D., Favaretto, A. G., Tamberi, S., Bianchi, G., et al. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.08.005 · Cited by 26
Discovery of predictive biomarkers for cancer therapy through computational approaches
Wang, X., Nguyen, J., Nader, K. M., Miihkinen, M., Wall, P., Singhal, A., Bedard, P. L., Ideker, T., Aittokallio, T. A., & Haibe‐Kains, B. (2026) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01109-8 · Cited by 31
Ardolino, L., Lau, B., Wilson, I., Chen, J., Borella, L., Stone, E. C. A., & Lim, E. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.701424 · Cited by 15
Alhesa, A., Awad, H., Bloukh, S., Al-Balas, M., El‐Sadoni, M., Qattan, D., Azab, B., & Saleh, T. (2022) · International Journal of Immunopathology and Pharmacology · doi:10.1177/03946320221078433 · Cited by 16
Abuhadra, N. K., Sun, R., Litton, J. K., Rauch, G. M., Yam, C., Chang, J. T., Seth, S., Bassett, R. L., Lim, B., Thompson, A. M., et al. (2022) · Cancers · doi:10.3390/cancers14051323 · Cited by 16
“Additionally, with the recent approval of neoadjuvant pembrolizumab for TNBC [34], the implications of our findings in the setting of immune checkpoint inhibitor therapy remain to be investigated.”
BackgroundGoda, N., Nakashima, C., Nagamine, I., & Otagaki, S. (2022) · Cancers · doi:10.3390/cancers14092138 · Cited by 19
“This provides a strong rationale for the inhibition of tumors from escaping anticancer immune mechanisms, such as immune checkpoint inhibitors, including programmed death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), by immunotherapies in TNBC [9,10].”
BackgroundVathiotis, I. A., Trontzas, I. P., Gavrielatou, N., Gomatou, G., Syrigos, N. K., & Kotteas, E. A. (2022) · Clinical Breast Cancer · doi:10.1016/j.clbc.2022.06.004 · Cited by 16
Triple-negative breast cancer and radiation therapy
Bessa, J. D. F., & Marta, G. N. (2022) · Reports of Practical Oncology & Radiotherapy · doi:10.5603/rpor.a2022.0025 · Cited by 24
Chung, C., Yeung, V. T. Y., & Wong, K. C. W. (2022) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552221119797 · Cited by 17
“141,142 In light of the clinical ef fi cacy of ICIs in the metastatic setting, the role of these agents in the early (perioperative) TNBC was investigated .143,144 Although ICIs have increased pCR rates, especially for PD-L1 positive tumors, the predictive role of PD-L1 is not clearly de fi ned in early TNBC. 145 There…”
BackgroundInfluentialChung, W.-S., Chen, S., Ko, T., Lin, Y., Lin, S., Lo, Y., Tseng, S.-C., & Yu, C. (2022) · Cancers · doi:10.3390/cancers14174170 · Cited by 19
Atkins, M. B., Abu‐Sbeih, H., Ascierto, P. A., Bishop, M., Chen, D. S., Dhodapkar, M. V., Emens, L. A., Ernstoff, M. S., Ferris, R. L., Greten, T. F., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005413 · Cited by 15
Immune checkpoint inhibitor-mediated colitis is associated with cancer overall survival
Weingarden, A. R., Gubatan, J. M. B., Singh, S., Balabanis, T., Patel, A., Sharma, A., & Habtezion, A. (2022) · World Journal of Gastroenterology · doi:10.3748/wjg.v28.i39.5750 · Cited by 18
Preoperative Systemic Therapy for Breast Cancer
Kodali, A., & Gadi, V. K. (2022) · Surgical Clinics of North America · doi:10.1016/j.suc.2022.08.017 · Cited by 15
Khadela, A. D., Soni, S., Megha, K., Shah, A. C., Pandya, A. J., Kothari, N. R., Shah, I., & Avinash, C. B. (2022) · Medical Oncology · doi:10.1007/s12032-022-01922-6 · Cited by 16
“The recommended dose of Pembrolizumab is 200 mg every 3 weeks or 400 mg every 6 weeks as an IV infusion over 30 min with neoadjuvant therapy continuing for 24 weeks and adjuvant therapy for 27 weeks [51].”
MethodNeoadjuvant immune checkpoint inhibition in the management of glioblastoma: Exploring a new frontier
Frederico, S. C., Darling, C., Bielanin, J. P., Dubinsky, A. C., Zhang, X., Hadjipanayis, C. G., & Kohanbash, G. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1057567 · Cited by 15
“Findings from this study demonstrated that among participants diagnosed with early, untreatable stage 2/3 TNBC, the pCR was significantly higher among participants in the cohort who received neoadjuvant pembrolizumab plus neoadjuvant chemotherapy compared to those who received neoadjuvant chemotherapy plus neoadjuvant…”
ResultEnsenyat-Méndez, M., Orozco, J. I. J., Llinàs‐Arias, P., Íñiguez-Muñoz, S., Baker, J. L., Salomon, M. P., Martí, M., DiNome, M. L., Cortés, J., & Marzese, D. M. (2023) · Communications Medicine · doi:10.1038/s43856-023-00311-y · Cited by 19
“15 .”
InfluentialStephen, B., Hajjar, J., Sarda, S., Duose, D. Y., Conroy, J. M., Morrison, C., Alshawa, A., Xu, M., Zarifa, A., Patel, S. P., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007236 · Cited by 19
CD24hiCD27+ Bregs within Metastatic Lymph Nodes Promote Multidrug Resistance in Breast Cancer
Huang, H., Yao, Y., Shen, L., Jiang, J., Zhang, T., Xiong, J., Li, J., Sun, S., Zheng, S., Jia, F., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-1759 · Cited by 18
Moldoveanu, D., Hoskin, T. L., Day, C. N., Schulze, A. K., Goetz, M. P., & Boughey, J. C. (2023) · Breast Cancer Research and Treatment · doi:10.1007/s10549-023-07152-2 · Cited by 15
“In these tumor types, total pCR rates as high as 65% can be achieved [11, 19].”
Hiraga, T. (2024) · International Journal of Oncology · doi:10.3892/ijo.2024.5623 · Cited by 18
Santis, P. D., Perrone, M., Guarini, C., Santoro, A. N., Laface, C., Carrozzo, D., Oliva, G. R., & Fedele, P. (2024) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2024.00215 · Cited by 20
Guo, J., Meng, W., Li, Q., Zheng, Y., Yin, H., Liu, Y., Zhao, S., & Ma, J. (2024) · Bioengineering · doi:10.3390/bioengineering11070663 · Cited by 17
Evolving Management of Breast Cancer in the Era of Predictive Biomarkers and Precision Medicine
Afzal, M. Z., & Vahdat, L. T. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14070719 · Cited by 22
“It is further observed that in Impassion 031 and KEYNOTE 522, the PD-L1 subclasses [161,162].”
BackgroundLCP1 correlates with immune infiltration: a prognostic marker for triple-negative breast cancer
Pan, S., Wan, M., Jin, H., Ning, R., Zhang, J., & Han, X. (2024) · BMC Immunology · doi:10.1186/s12865-024-00635-x · Cited by 15
“According to extensive clinical studies, immune checkpoint inhibitors (ICIs) such as pembrolizumab and atezolizumab have demonstrated efficacy in treating early-stage or metastatic TNBC [11, 12].”
BackgroundHe, M., Jiang, Y., Gong, Y., Fan, L., Liu, X., Liu, Y., Tang, L.-C., Mo, M., Hou, Y., Di, G., et al. (2024) · BMJ · doi:10.1136/bmj-2024-079603 · Cited by 18
Multidisciplinary considerations in the treatment of triple‐negative breast cancer
Bellon, J. R., Burstein, H. J., Frank, E. S., Mittendorf, E. A., & King, T. A. (2020) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21643 · Cited by 15
Takeshita, T., Torigoe, T., Yan, L., Huang, J. L., Yamashita, H., & Takabe, K. (2020) · Cancers · doi:10.3390/cancers13010110 · Cited by 15
Xu, J., Xu, N., Bai, Y., Liu, R., Mao, C., Sui, H., Wang, X., Jiang, Q., & Dou, Y. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1864908 · Cited by 15
van der Noordaa, M. E. M., Ioan, I., Rutgers, E. J. T., van Werkhoven, E. D., Loo, C. E., Voorthuis, R. A. B., Wesseling, J., van Urk, J., Wiersma, T., Dezentjé, V. O., et al. (2021) · Annals of Surgical Oncology · doi:10.1245/s10434-021-09865-4 · Cited by 15
Heparanase is a novel biomarker for immune infiltration and prognosis in breast cancer
Yang, W., Shi, L., Wang, X., & Yang, G. (2021) · Aging · doi:10.18632/aging.203489 · Cited by 16
Kim, H., Kim, H. J., Kim, H.-S., Kim, H. R., Jo, H., Hong, J.-H., Kim, R., Kim, J., Ahn, J. S., Im, Y., et al. (2021) · Cancers · doi:10.3390/cancers13225835 · Cited by 19
Ji, Q., Ding, J., Hao, M., Luo, N., Huang, J., & Zhang, W. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.795650 · Cited by 22
Evolving management of HER2+ breast cancer brain metastases and leptomeningeal disease
Mills, M. N., King, W., Soyano, A. E., Piña, Y., Czerniecki, B. J., Forsyth, P. A., Soliman, H. H., Han, H. S., & Ahmed, K. A. (2022) · Journal of Neuro-Oncology · doi:10.1007/s11060-022-03977-x · Cited by 16
“1 3 metastases as well as the well-defined role for PD-1/PD-L1 inhibitors in the metastatic and neoadjuvant triple negative breast cancer settings [114, 146, 147], there has been interest in the study of immune checkpoint inhibitors in the management of BCBM and LMD.”
BackgroundThe top 100 most cited articles on triple-negative breast cancer: a bibliometric analysis
Huang, Y., Chen, P., Peng, B., Liao, R., Huang, H., Huang, M., Chen, Q., Li, S., Guo, S., & Zheng, S. (2022) · Clinical and Experimental Medicine · doi:10.1007/s10238-022-00800-9 · Cited by 16
“For example, Pembrolizumab was used in patients with early [25], late [26], metastatic [27] TNBC, and it was concluded that the addition of Pembrolizumab to neoadjuvant chemotherapy in patients with early TNBC was beneficial in improving the pCR.”
MethodLaws, A., Pastorello, R., Dey, T., Grossmith, S. C., King, C., McGrath, M., Schnitt, S. J., Mittendorf, E. A., & King, T. A. (2022) · Annals of Surgical Oncology · doi:10.1245/s10434-022-12054-6 · Cited by 15
Azim, H. A., Shohdy, K. S., Elghazawy, H. I., Salib, M. M., Almeldin, D. S., & Kassem, L. M. H. (2022) · Biomarkers · doi:10.1080/1354750x.2022.2112614 · Cited by 20
Gastrointestinal Microbiota and Breast Cancer Chemotherapy Interactions: A Systematic Review
Csendes, D., Gutlapalli, S. D., Prakash, K., Swarnakari, K. M., Bai, M., Manoharan, M. P., Raja, R., Jamil, A., Desai, A., Desai, D. M., et al. (2022) · Cureus · doi:10.7759/cureus.31648 · Cited by 16
“therapy combinations may cause 53% to 78% of patients to experience grade three or higher treatmentrelated adverse events [4-6].”
BackgroundChartier, S., Brochard, C., Martinat, C., Coussy, F., Féron, J.-G., Kirova, Y., Cottu, P. H., Marchiò, C., & Vincent‐Salomon, A. (2022) · Histopathology · doi:10.1111/his.14852 · Cited by 16
“The US Food and Drug Administration (FDA) approved the use of atezolizumab, an antiprogrammed death ligand-1 (PD-L1) monoclonal antibody, for managing unresectable PD-L1-positive TNBCs based on the IMPassion130 study,(17) and pembrolizumab for high-risk, early-stage TNBCs in the neoadjuvant setting and for locally adv…”
BackgroundVidra, R., Nemeș, A., Vidrean, A., Pintea, S., Tintari, S., Deac, A. L., & Ciuleanu, T. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.11014 · Cited by 15
Perturbing local steroidogenesis to improve breast cancer immunity
Zhao, Q., Pramanik, J., Lu, Y., Homer, N. Z. M., Imianowski, C. J., Zhang, B., Iqbal, M., Shaji, S. K., Morris, A. C., Roychoudhuri, R., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59356-3 · Cited by 15
Cheung, A., Wang, D., Quintayo, M. A., Yerofeyeva, Y., Spears, M., Bartlett, J. M. S., Stein, L. D., Bayani, J., & Yaffe, M. J. (2025) · Breast Cancer Research · doi:10.1186/s13058-025-02038-1 · Cited by 16
Ren, X., Zheng, L., Huang, L., & Zhao, J. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1591745 · Cited by 17
“The KEYNOTE trials have shown that incorporating immune checkpoint inhibitors into chemotherapy regimens markedly enhances recurrence-free survival (Cortes et al., 2022; Schmid et al., 2020).”
Mayerhoefer, M. E., Kienzle, A., Woo, S., & Vargas, H. A. (2025) · Radiology · doi:10.1148/radiol.241030 · Cited by 19
Shen, L., Zhang, X., Ji, K., Lu, L., Wang, Q., Guan, Q., Yan, S., Zhou, Y., Yang, Y., Huo, Z., et al. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00974-8 · Cited by 14
Bertucci, A., Bertucci, F., Zemmour, C., Lerebours, F., Pierga, J., Lévy, C., Dalenc, F., Grenier, J., Petit, T., Berline, M., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.575978 · Cited by 15
ASCO 2020: highlights in breast cancer
Bartsch, R. (2021) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-021-00674-9 · Cited by 17
Yoga Improves Quality of Life among Breast Cancer Patients
Setiawan, H., Ariyanto, H., Khaerunnisa, R. N., Firdaus, F. A., & Fitriani, A. (2021) · Faletehan Health Journal · doi:10.33746/fhj.v8i01.159 · Cited by 15
Yordanova, M., Hubert, A., & Hassan, S. N. (2021) · Pharmaceuticals · doi:10.3390/ph14121270 · Cited by 16
Moloney, C., & Shiely, F. (2022) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2022.03.011 · Cited by 19
Liu, G., Qiu, Y., Zhang, P., Chen, Z., Chen, S., Huang, W., Wang, B., Yu, X., & Guo, D. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091762 · Cited by 14
Manspeaker, M. P., O’Melia, M. J., & Thomas, S. N. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005079 · Cited by 14
Mouron, S. A., Bueno, M. J., Lluch, A. M., Manso, L., Calvo, I., Cortés, J., García-Sáenz, J. Á., Gil‐Gil, M., Martínez-Jáñez, N., Apala, J. V., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-35065-z · Cited by 14
Chen, Y., Wang, X. L., Du, F., Yue, J., Si, Y., Zhao, X., Cui, L., Zhang, B., Bei, T., Xu, B., et al. (2023) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2022.0525 · Cited by 19
Bou-Dargham, M. J., Sha, L., Sarker, D. B., Krakora-Compagno, M. Z., Chen, Z., Zhang, J., & Sang, Q. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119355 · Cited by 15
“Another accelerated approval was given to pembrolizumab in 2020 (KEYTRUDA ® ) in combination with chemotherapy (paclitaxel protein-bound/paclitaxel, or gemcitabine plus carboplatin) for the treatment of patients with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1 [3].”
Background
Metadata
- Authors
- Schmid, P., Cortes, J., Pusztai, L., McArthur, H., Kümmel, S., Bergh, J., Denkert, C., Park, Y. H., Hui, R., Harbeck, N., Takahashi, M., Foukakis, T., Fasching, P. A., Cardoso, F., Untch, M., Jia, L., Karantza, V., Zhao, J., Aktan, G., Dent, R., & O’Shaughnessy, J.
- Affiliations
- Queen Mary University of London (GB)
- IOB Institute of Oncology, Quiron Group;Vall d’Hebron Institute of Oncology (VHIO), Madrid & Barcelona, Spain
- Yale Cancer Center (US)
- Cedars-Sinai Medical Center (US)
- Kliniken Essen-Mitte (DE)
- Karolinska University Hospital (SE)
- Philipps University of Marburg (DE)
- Samsung Medical Center (KR)
- The University of Sydney (AU)
- Ludwig-Maximilians-Universität München (DE)
- Sapporo National Hospital (JP)
- Universitätsklinikum Erlangen (DE)
- Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal
- Helios Hospital Berlin-Buch (DE)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- National University of Singapore (SG)
- Baylor University Medical Center (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-02-27
- Volume
- 382
- Issue
- 9
- Pages
- 810-821
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3006930853
- Cited by
- 3,270
- References
- 31
- Citations by year
- 2026: 580 · 2025: 576 · 2024: 552 · 2023: 500 · 2022: 514 · 2021: 391 · 2020: 152
- FWCI
- 133.41
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA (N/A)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › MRI in cancer diagnosis
- Keywords
- pembrolizumab, triple-negative breast cancer, early breast cancer, neoadjuvant immunotherapy, neoadjuvant chemotherapy, paclitaxel, carboplatin, pathological complete response, event-free survival, immune checkpoint inhibitors, doxorubicin-cyclophosphamide, epirubicin-cyclophosphamide
- MeSH terms
- Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Cyclophosphamide, Doxorubicin, Female, Humans, Middle Aged, Neoplasm Staging, Epirubicin, Carboplatin, Paclitaxel, Neoadjuvant Therapy, Kaplan-Meier Estimate, Intention to Treat Analysis, Antibodies, Monoclonal, Humanized, Triple Negative Breast Neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.